A Phase 3 interventional study of Latozinemab in Neurodegenerative Diseases, sponsored by Alector Inc.. Terminated at 18 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-21.
Sponsored by Alector Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies in Neurodegenerative Diseases with a site in United States — 45 open to participants now, 58 under way, 4 of them phase 3. Neurodegenerative Diseases · United States.
Among the 176 studies in Neurodegenerative Diseases with a site in United States, this one is the 103rd largest by enrollment of the 120 interventional ones that give a count, is one of 19 that started in 2023, is one of 22 in phase 3, and was the 144th registered.
436 studies on the registry are indexed under Neurodegenerative Diseases; 143 are open to participants now.
Browse Neurodegenerative Diseases studies →45 of the 176 studies in Neurodegenerative Diseases with a site in United States are open now. Recruiting first, the newest first:
Vima Therapeutics · Sites in United States, Canada
Ages 18–65
The University of Texas Medical Branch, Galveston · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Australia, New Zealand and 1 more country
Ages 50–85
Eli Lilly and Company · Sites in United States, Japan, Korea, Republic of and 1 more country
Ages 55–85
Longevity Metrics, Inc. · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger; 20 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 45 · Phase 3 24 · Phase 4 1
First in 1993; this study’s year is marked. 19 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 54 across 265 interventional studies indexed under Neurodegenerative Diseases.
Median enrollment 63 across the 120 interventional studies, 85 across the 54 observational. Of the 104 that completed or were terminated, 33 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
80 of 176 have an industry lead sponsor. The 10 most frequent:
Alector Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Alector Inc. has 1 study filed under Neurodegenerative Diseases — fewer than ten, so there is no comparison to draw.
18 of the studies in Neurodegenerative Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04838301University of ArizonaAllopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease | 2026-11-18 |
| NCT06268886Bristol-Myers SquibbStudy to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease | 2026-12-17 |
| NCT02414178Washington University School of MedicineF 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) | 2027-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT02553525Duke UniversityEffects of Stimulation Patterns of Deep Brain Stimulation | 2027-03 |
Add all 18 to your calendar (.ics) → With an account.
Among the 176 studies in Neurodegenerative Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study
This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study.
All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Latozinemab (AL001) administered by IV infusion over 60 minutes, q4w
Drug: Latozinemab
All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks
Also known as: AL001
Number of participants receiving latozinemab
Number of participants receiving latozinemab
Time frame: Through study completion, up to 190 weeks
Duration of treatment with latozinemab
Duration of treatment with latozinemab
Time frame: Through study completion, up to 190 weeks
Incident of adverse events (AEs) and serious adverse events (SAEs)
Number and percentage of participants of AEs or SAEs
Time frame: Through study completion, up to 190 weeks
Nature and severity of AEs and SAEs
Severity of AEs and SAEs according to the World Health Organization (WHO) toxicity grading scale
Time frame: Through study completion, up to 190 weeks
Incidence of ADAs to latozinemab
Number and percentage of participants with anti-Drug Antibodies (ADA) titer over study time points
Time frame: Through study completion, up to 190 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in Sep 2025, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Latozinemab
Alector Inc.